Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some pharmacology/interaction claims (statin class, grapefruit juice interaction, alcohol-related risk framing) partially align with the provided label excerpts, but several claims about alcohol and the nature/extent of alcohol effects are unsupported by the supplied prescribing information. Indication/dosing/safety-monitoring/contraindications/boxed warnings are not addressed by the AI claims.
Category Scores
Accurate Statements
Grapefruit juice interacts with statins by inhibiting the enzyme responsible for breaking down these medications in the gut.
Label 7.2: Grapefruit juice contains components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin.
Grapefruit juice can increase statin levels in the blood and potentially lead to side effects.
Label 7.2: Can increase plasma concentrations of atorvastatin. (Label excerpt provided does not explicitly state side effects from this mechanism, but increased plasma concentrations are supported.)
Lipitor (atorvastatin) belongs to the class of drugs called statins.
Label excerpts refer to 'statins' and 'with other drugs in this class' and discuss statins generally (e.g., 5 WARNINGS, 7 DRUG INTERACTIONS).
Lipitor (atorvastatin) is a cholesterol-lowering medication.
Label 1.2 Hyperlipidemia: 'reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C' and other lipid reductions.
Unsupported Statements
Research on the impact of white wine consumption on statin metabolism and efficacy is limited.
No information about white wine or alcohol consumption research is included in the provided label excerpts.
Results on the impact of alcohol (white wine) on statin metabolism and efficacy are mixed.
No information about alcohol/white wine effects on statin metabolism or efficacy is included in the provided label excerpts.
Drinking moderate amounts of alcohol may increase the risk of side effects when taking statins.
No alcohol-related risk statement is included in the provided label excerpts.
Consuming alcohol while taking atorvastatin (Lipitor) can lead to a higher risk of adverse effects such as muscle pain and weakness in some individuals.
No alcohol-related increase in muscle pain/weakness is included in the provided label excerpts (label excerpts address myopathy/rhabdomyolysis risk generally and via specific drug classes, but not alcohol).
Contradictions
Important Omissions
For claims involving drug interactions, the label excerpt specifically provides warnings for strong CYP3A4 inhibitors (e.g., clarithromycin, protease inhibitors, itraconazole) and dose cautions; the AI response only addresses grapefruit juice and does not mention these label-supported interaction cautions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Alcohol-related claims are unsupported by the provided label excerpts; if treated as label-accurate, this could mislead users about interaction risks. Grapefruit juice interaction claims are broadly consistent with the label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Alcohol/white-wine-related interaction/effect claims are not supported by the provided LIPITOR label excerpts.
Suggested Improvement
Remove or qualify alcohol/white-wine statements unless supported by additional label text. Limit interaction statements to label-supported items provided (e.g., grapefruit juice via CYP3A4 inhibition; strong CYP3A4 inhibitors and cyclosporine dose limits, as available).